drugset / Trial / NCT02107391

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

NCT02107391

Phase 2 Completed 63 enrolled SOTIO a.s.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.

Timeline

Start
2012-03
Primary completion
2015-12
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Goserelin Other / unclassified
Comparator Leuprolide Other / unclassified
Subject STAPULDENCEL Vaccine

Indications